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Abstract 
Human urinary kallikrein was purified by gel filtra- 
tion on Sephacryl S-200 and affinity chromatography on 
aprotlnin-Sepharose, followed by ion exchange chromato- 
graphy on DEAE-Sepharose. In dodeeylsulfate gel electro- 
phoresis two protein bands with molecular weights of 41,000 
and 34,000 were separated. The amino acid composition 
and the carbohydrate content of the kalllkrein preparation 
were determined; isoleuelne was identified as the only 
aminoterminal amino acid. The bimolecular veloeity constant 
for the inhibition by dilsopropyl fluorophosphate was 
determined as 9 +2 I tool -1 min -1. The hydrolysis of a 
number of substrates was investigated and AePheArgOEt 
was found to be the most sensitive substrate for human 
urinary kallikrein. Using this substrate an assay method 
for kallikrein in human urine was developed. 
It was shown by radiolmmunoassay that pig pan- 
creatic kallikrein can be absorbed in the rat intestinal 
tract. Furthermore, in dogs the renal excretion of glandular 
kallikrein from blood was demonstrated by radioimmuno- 
logical methods. 
Introduction 
In the mammalian organism, organ or tissue 
kallikreins are present in salivary glands, pancreas, 
kidney, urine, small and large intestine and in 
low concentrations also in blood [1]. Kallikreins 
found in these tissues are immunologicaUy and bio- 
chemically very similar as demonstrated byFRITZ 
et al. for the pig [2]. Glandular kallikreins are 
assumed to be involved in various biological 
processes uch as adsorption of water, electro- 
lytes and hexoses in the intestine [3, 4], lowering 
of the blood sugar level, probably by glucose 
uptake into muscle cells [5], cell proliferation 
[6] and stimulation of other biological hormone 
systems [7, 8]. 
Of the palette of tissue kallikreins human 
urinary kallikrein was selected for investigations. 
Materials and methods 
CN-Br-activated Sepharose and Sephacryl S-200 were 
products from Pharmacia Fine Chemicals, Sweden. D- 
Val-Leu-ArgOEt, D-VaI-Leu-ArgNHNp and other nitro- 
anilides were kindly provided by KABI, M61ndal, 
Sweden; Z-TyrONp and BzArgOEt were purchased from 
SERVA, Heidelberg. AcPheArgOEt was synthesized accor- 
ding to FIEDLER et al. [9]. Trasylol was a gift from 
Bayer AG, Leverkusen. Human urinary kallikrein activity 
was assayed with peptide esters and nitroanilides as 
substrates as described [9, 10]. Dog blood pressure was 
measured according to Fm~v et al. [11]. Human urinary 
kallikrein content in urine samples was assayed by radio- 
immunoassay as described by MANN et al. [12]. Poly- 
acrylamide gel electrophoresis were performed as described 
by MAURER [13]. For amino acid analysis samples were 
hydrolyzed in vacuo at 100~ with 5.7 N HCI for 20, 
40 and 80 h and analyzed on a Durrum D 500. The 
bimolecular velocity constant for the inhibition of human 
urinary kallikrein by DFP was determined according to 
FIEDLER et al. [14]. Carbohydrate content of kallikreins 
were determined as described by KaYSTAL et al. [15]. The 
complex of human urinary kallikrein and Trasylol was 
obtained by incubating enzyme and inhibitor in a 1:2 
ratio (w/w) at 37~ for 10 min before analysis. 
Table 1 
Isolation of human urinary kallikrein. 
Steps Purification a 
Collection of human male urine 
Dialysis 
Lyophilization 
Extraction of the crude urine powder 
Sephacryl S-200 1 
Trasylol Sepharose 89 
DEAE-Sepharose 240 
a Substrate: AcPheArgOEt. 
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Results and Discussion 
Isolation and characterization 
Isolation of human urinary kallikrein was 
achieved by the procedure summarized in Table 
1, slightly different as reported earlier [16]. 
Human urinary kaUikrein obtained after isolation 
was subjected to polyacrylamide gel electro- 
phoresis at pH 7.5 as shown in Figure 1. 
After reduction with dithioerythriol the 
following pattern was obtained (Fig. 2). 
Amino acid analysis of human urinary 
kallikrein and the determination f carbohydrate 
content were done by common methods. The Asp 
results are shown in Tables 2 and 3. According Thr 
to our results, the amino acid composition of Ser 
human urinary kallikrein and pig pancreatic Glu 
Pro 
fl-kallikrein are very similar. Gly 
In Table 4 constants of the inhibition of Ala 
kallikreins and other serine proteases by DFP Cys 
are compiled. The constants obtained for tissue Val 
kallikreins are all of the same order of magni- Met 
rude. lie 
Leu 
Isoleucine was identified by high pressure Tyr 
liquid chromatography after Edman degradation Phe 
[17] as the N-terminal amino acid of human- Lys 
His  urinary kallikrein. Arg 
Homogeneity of the enzyme preparation is Trp 
strongly indicated by the presence of only one 
amino terminal mino acid and by the results 
of the electrophoretic investigations (cf. Fig. 1). 
No residual protein remains at the position of 
the single kallikrein band (gel A) after complex 
formation with Trasylol (gel B), i.e. the kallikrein 
Table 2 
Amino acid composition of kallikreins from human urine 
and porcine pancreas (residues per mole). Tryptophan 
was not determiried, cystein after performic acid oxidation. 
Human urinary Porcine pancreatic 
kallikrein fl-kallikrein [ 18] 
23 28 
14 15 
14 14 
28 23 
14 16 
22 22 
14 13 
10 10 
18 10 
4 4 
8 12 
20 20 
6 7 
10 10 
8 10 
9 8 
6 3 
? 7 
Figure 1 
Acrylamide gel electrophoresis (7.5% gel, pH 7.5) of human 
urinary kallikrein. A, purified enzyme; B, purified enzyme 
samples with Trasylol. 
Figure 2 
SDS-polyacrylamide g l electrophoresis (7.5% gel, pH 7.2; 
the enzyme was incubated with 10% dithioerythriol, 6 N urea 
and 10% SDS at 45~ for 60 min) of human urinary kalli- 
krein (B). Molecular weight was estimated by SDS electro- 
phoresis using a protein standard of Bio-Rad (A). 
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Table 3 
Carbohydrate content of human urinary kallikrein and 
porcine pancreatic kallikrein. 
Kallikrein from Carbohydrate content 
g/100 g protein 
Porcine pancreas [ 18] 
form A 5.6 
form B 11.5 
Human urine 10.5-15.6 
Table 4 
Kinetic constants for the inhibition of different serin 
proteases by DFP (pH 7.2, 25~ R. Geiger and U. 
Stuckstedte, unpublished. 
Enzyme k (1 mol -l min -1) 
Human urinary kallikrein 9 + 2 
Human large intestine kallikrein [ 19] 4 
Porcine pancreatic kallikrein [14] 8 + 1 
Human plasma kallikrein 320 _+ 20 
Trypsin [20] 300 
Chymotrypsin [20] 2,700 
Acetylcholinesterase [20] 13,000 
Table 5 
Assay of human urinary kallikrein using the substrate 
Ac-Phe-ArgOEt. 
2.00ml 0.15 M sodium diphosphate buffer, pH 
8.7, containing 0.15 M semicarbazidium 
chloride and 0.0375 M glycine 
0.10 ml 0.03 MNAD 
0.10 ml 0.015 M AcPheArgOEt acetate 
0.02 ml alcohol dehydrogenase (100 mg/3.4 ml) 
(0.28 + x) ml water 
5 min preincubation at25 ~ 
(0.5 - x) ml enzyme solution 
Final volume: 3 ml 
The change in absorbance is monitored for 10 min at 
366 nm. 
preparation contains exclusively active enzyme 
molecules. 
Assay methods 
The methods for the determination f tissue 
kallikreins in urine and other body fluids are 
either rather cumbersome or insensitive. With 
preparations of human urinary kallikrein, AcPhe- 
ArgOEt was found to be the most rapidly 
hydrolyzed substrate described as yet [9]. 
Therefore, a highly sensitive assay for human 
urinary kallikrein could be developed employing 
Ac-Phe-ArgOEt as substrate. The assay (Table 5) 
is analogous to that with Bz-ArgOEt developed 
by TRAUTSCHOLD and WEaLE [21]. The reaction 
sequence is shown in Figure 3. The sensitivities 
of this and other assays for human urinary 
kallikrein are compiled in Table 6. The sen- 
sitivity of the assay allows the convenient 
measurement of the esterase activity of human 
urine. Urine samples of 20-100 ~1 cause a linear 
absorbance increase of 0.04 to 0.2 per 10 min. 
Known amounts of human urinary kallikrein 
added to urine samples raised the esterase 
activity to the expected extent. If the urine 
samples contain ethanol it has to be removed 
by dialysis. Therefore, ethanol intake should be 
avoided uring the urine collection period. 
A number of experiments were undertaken 
to verify that the esterase activity reflects the 
kallikrein content of urine. Trasylol completely 
inhibited the esterase activity. Dialysed urine 
samples of ten different persons were assayed. 
The results were compared with those obtained 
by the dog blood pressure assay, by a radio- 
immunoassay for human urinary kallikrein and 
by the assay with D-Val-Leu-ArgNHNp as 
substrate (Fig. 4). Though the correlation co- 
efficient of the results of the Ac-Phe-ArgOEt 
assay and the dog blood pressure assay (Fig. 
4a) is rather close to 1, a considerable scattering 
of the data is observed. This is not too surprising, 
since the coefficient of variation of the blood 
pressure assay for kallikrein amounts to 20%. 
The correlation between the Ac-Phe-ArgOEt 
Ac-Phe-ArgOEt Kallikrein Ac-Phe-Arg + CzHsOH 
CzHsOH + NAD Alkoholdehydrogenase~ CH3__C//0 
1~ ) \H  
+ NADH 2 Figure 3 Reaction scheme of kallikrein assay using Ac- 
Phe-ArgOEt as substrate. 
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Table 6 
Absorbance changes in assay of human urinary kallikrein with various substrates. (Reaction 
volume 3 ml, cuvette light path 1 cm.) 
Blank Reaction 
(AA. 103 • min -1) 
(AA. 103 x min -1 x U -1) Relative 
sensitivities 
Ac-Phe-ArgOEt 0.6 1100 
D-Val-Leu-ArgOEt 0.6 430 
Bz-ArgOEt 0.5 24 
Z-TyrONp 15 460 
D-Val-Leu-Arg-p-nitr anilide 0.0 29 
D-Pro-Phe-Arg-p-nitranilide 3 
Tos-Gly-Pro-Arg-p-nitr anilide 1 
Bz -Phe-Val-Arg-p-nitr anilide 0.3 
Glu-Gly-Arg-p-nitranilide 0.3 
46 
20 
1 
19 
1,2 
assay and both the radioimmunoassay (Fig. 4b) 
and the D-Val-Leu-Arg-p-nitroanilide assay is 
even more satisfactory. The excellent correlation 
between the two enzymatic assays (Fig. 4c) 
strongly suggests that in both assays the same 
enzyme is determined. For a mixture of enzymes 
a similarly good correlation would only be ex- 
pected if these enzymes were always excreted in 
identical ratios9 
These arguments are strongly in favour of 
the presumption that in the assay using AcPhe- 
ArgOEt only the kallikrein content of urine is 
determined. 
Functional aspects 
During recent years we widely applied the 
radioimmunoassay methods in studies on the 
4 o 
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Figure 4 
Comparison of the Ac-Phe-ArgOEt assay for human urinary kallikrein with the blood pressure assay (a), the adioimmuno- 
assay (b) and the D-Val-Leu-ArgNHNp assay (c). Ten samples of human urine were measured. 
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Table 7 
Biological effects of pig pancreatic kaUikrein. 
1. Stimulation ofintestinal bsorption fvarious ubstances 
like glucose, amino acids and vitamin B12 
2. Stimulation fcell proliferation 
3. Stimulation of number and motility of spermatozoa in 
patients with astenozoospermia and oligozoospermia 
4. Enhancing effect on muscular glucose uptake in patients 
with maturity onset diabetes 
5. Reduction of blood pressure in patients with essential 
hypertension 
physiological role and pharmacological mechan- 
ism of action of glandular kallikreins. 
Intest inal  absorption. In certain pathological 
disorders an improvement is observed after oral 
administration or intramuscular injection of pig 
pancreatic kallikrein (3, 4 and 5 in Table 7). 
These findings suggest hat glandular kallikrein 
can be absorbed intestinally and causes the 
observed effects after being transferred into the 
circulation. 
In order to examine whether kallikrein can be 
absorbed by the intestine pig pancreatic kalli- 
krein was injected into the lumen of the duo- 
denum of anesthetized rats; the thoracic duct 
lymph was collected and blood samples were 
obtained from the tail vein. By applying the 
radioimmunoassay it was possible to show that 
pig pancreatic kallikrein appeared both in the 
thoracic duct lymph and in the blood demon- 
strating intestinal absorption of the kallikrein. 
These results provide a rational basis for the oral 
administration of pig pancreatic kallikrein: the 
kallikrein can be transferred from the lumen of 
the intestine into the circulation. The mechanism 
of action of the absorbed kallikrein which results 
in the improvement of pathologic disorders is 
not yet understood. 
Rena l  excretion o f  g landular  kall ikrein. 
Recently it was possible to demonstrate the 
presence of a glandular kallikrein-like antigen 
in porcine and human blood by radioimmuno- 
assays [1, 22, 23]. This finding led us to the de- 
duction that glomerular filtration of the glandular 
kallikrein in the blood might partly be respon- 
sible for the occurrence of glandular kallikrein 
in urine. Our experiments in the renal excretion 
of pig pancreatic kallikrein after intravenous 
infusion in dogs corroborate this deduction 
[23, 24]. 
Pig pancreatic kallikrein was infused into 
the femoral vein of anesthetized ogs. Blood 
samples were drawn from the artery and urine 
was collected from the catheterized urinary 
bladder. The urine and blood samples were 
measured by radioimmunoassay. The total ex- 
creted kallikrein in five experiments was 1-3% 
of the administered dose. The relative clearance 
of porcine pancreatic kallikrein, related to 
inulin, was approximately 4%, being in the same 
range as the amylase clearance determined in 
man. Calculated from the clearance found for 
pig pancreatic kallikrein in the dog (approxi- 
mately 2.5 ml/min) and the (preliminary) con- 
centration of glandular kallikrein in blood 
(5-20 ng/ml)a daily excretion of about 50/tg 
kallikrein would result which is in the range of 
several 10% of the daily excretion of urinary 
kallikrein in man. 
The results suggest hat urinary kallikrein 
does not represent exclusively a kallikrein 
synthesized by the kidney and secreted irectly 
into the urine. Glomerular filtration of glandular 
kallikrein from the blood may contribute sig- 
nificantly to the excretion of kallikrein in urine. 
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Abbreviations 
Bz-ArgOEt: N"-Benzoyl-arginine ethyl ester; Z- 
TyrONp: Carbobenzoxytyrosine nitrophenyl ester; Ac-Phe- 
ArgOEt: Acetyl-phenylalanyl-arginine ethyl ester; D-Val- 
Leu-ArgOEt: D-valyl-leucyl-arginine ethyl ester; DFP: 
diisopropyl fluorophosphate. 
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